MeSH tree: C15.378.463.515.460
Five-year relative survival rates for all cancers combined have increased to 70% for people diagnosed during 2015 to 2021 in the United States, according to the "Cancer Statistics, 2026," report, published in CA: A Cancer ...
Jan 13, 2026
0
17
Rates of multiple myeloma (MM), the second most common blood cancer in the United States, are increasing and are twice as high in men than in women. A new study published online in Cancer provides insights that may help to ...
Jan 12, 2026
0
10
A new study maps the immune cell landscape of bone marrow in patients with multiple myeloma, a rare cancer that develops in the plasma cells of the bone marrow and has no cure. This large immune cell atlas, which includes ...
Jan 9, 2026
0
54
Multiple myeloma, a cancer of the bone marrow, remains difficult to treat despite modern CAR T cell therapies. In recent research, a team led by Dr. Armin Rehm presents an improved immunotherapy that recognizes two distinct ...
Jan 8, 2026
0
35
Researchers at the Indiana University Melvin and Bren Simon Comprehensive Cancer Center have uncovered biological differences in how multiple myeloma develops and progresses in men and in women. The rare blood cancer occurs ...
Dec 16, 2025
0
55
At the American Society of Hematology Conference in Orlando, new results from the MajesTEC-3 study show that combining teclistamab with daratumumab could help people with myeloma whose cancer has come back or hasn't responded ...
Dec 9, 2025
0
17
Patients who receive T-cell redirecting therapies are typically hospitalized for several days after treatment to watch for side effects. Now new research by Fox Chase Cancer Center physicians shows that these patients can ...
Dec 9, 2025
0
8
Research presented December 8 at the American Society of Hematology Conference in Florida, has shown that a new kind of CAR T-cell therapy, which generates CAR T-cells inside the body, could offer a faster, easier and more ...
Dec 8, 2025
0
11
Sensitive tests designed to detect very small numbers of remaining leukemia cells after treatment, known as measurable residual disease (MRD), may provide an early and reliable indicator of long-term outcomes for patients ...
Dec 8, 2025
0
8
Treatment with an immune and cancer cell-targeting antibody therapy eradicates residual traces of the blood cell cancer multiple myeloma, according to interim results from a clinical trial conducted by researchers at Sylvester ...
Dec 6, 2025
0
30
